Jindan Luo

Hangzhou, 310003, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization.

piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization.

Journal: Translational oncology
Published: October 03, 2025

CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement.

CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement.

Journal: Cancer research
Published: April 22, 2025

The roles and function of circular RNA in prostate cancer.

The roles and function of circular RNA in prostate cancer.

Journal: Gene
Published: April 06, 2025

SREBF1-mediated SND1 transcriptional activation promotes prostate cancer progression via MTDH interaction through the SESN2/AMPK/mTOR axis.

SREBF1-mediated SND1 transcriptional activation promotes prostate cancer progression via MTDH interaction through the SESN2/AMPK/mTOR axis.

Journal: Journal of translational medicine
Published: February 11, 2025

The urinary eccDNA landscape in prostate cancer reveals associations with genome instability and vital roles in cancer progression.

The urinary eccDNA landscape in prostate cancer reveals associations with genome instability and vital roles in cancer progression.

Journal: Journal of advanced research
Published: September 18, 2024

N6-methyladenosine-modified circRPS6KC1 regulated cellular senescence in prostate cancer via FOXM1/PCNA axis.

N6-methyladenosine-modified circRPS6KC1 regulated cellular senescence in prostate cancer via FOXM1/PCNA axis.

Journal: Cellular signalling
Published: August 30, 2024

PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer.

PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer.

Journal: Asia-Pacific journal of clinical oncology
Published: October 05, 2023

N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128-3p/MAPK1 axis.

N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128-3p/MAPK1 axis.

Journal: Cancer letters
Published: July 01, 2023

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance.

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance.

Journal: Drug design, development and therapy
Published: June 10, 2022

A single-dose, randomized, open-labeled, parallel-group study comparing the pharmacokinetics, pharmacodynamics and safety of leuprolide acetate microspheres 3.75 mg and Enantone® 3.75 mg in healthy male subjects.

A single-dose, randomized, open-labeled, parallel-group study comparing the pharmacokinetics, pharmacodynamics and safety of leuprolide acetate microspheres 3.75 mg and Enantone® 3.75 mg in healthy male subjects.

Journal: Frontiers in pharmacology
Published: June 10, 2022

FTO promotes clear cell renal cell carcinoma progression via upregulation of PDK1 through an m6A dependent pathway.

FTO promotes clear cell renal cell carcinoma progression via upregulation of PDK1 through an m6A dependent pathway.

Journal: Cell death discovery
Published: March 30, 2022

circKDM4C enhances bladder cancer invasion and metastasis through miR-200bc-3p/ZEB1 axis.

circKDM4C enhances bladder cancer invasion and metastasis through miR-200bc-3p/ZEB1 axis.

Journal: Cell death discovery
Published: June 23, 2021
Showing 1-12 of 29

Last Updated: 09/26/2026